Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
737 6 |
Ultima descărcare din IBN: 2021-11-10 10:49 |
SM ISO690:2012 TARAN, Natalia, DUMBRAVA, Vlada-Tatiana, TOFAN-SCUTARU, Liudmila. Hepatocarcinomul celular: răspândire, factori de risc şi obţiuni de tratament. In: Sănătate Publică, Economie şi Management în Medicină , 2014, nr. 5(56), pp. 138-142. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 5(56) / 2014 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
Pag. 138-142 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Liver cancer ranks the 6th place in the structure of oncological morbidity (749000 new cases) and third in cancer mortality structure (692000), representing 7% of all cancer cases. HCC represents more than 90% of primary liver cancer, being the primordial public health problem worldwide. Globally, approximately 54% of HCC cases causally relate to viral hepatitis B (400 million people), 31% of cases are caused by viral hepatitis C (170 million people infected) and the rest – 15% have other causes. The basic treatment of HCC is surgical. When properly selected, candidates resection and liver transplantation offers the best option for development (5-year survival rate is achieved in 60-80% of cases) and there are methods of choice in patients with early-stage tumors. |
||||||
Cuvinte-cheie viral chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, treatment methods, liver transplantation |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-58225</cfResPublId> <cfResPublDate>2014-10-31</cfResPublDate> <cfVol>56</cfVol> <cfIssue>5</cfIssue> <cfStartPage>138</cfStartPage> <cfISSN>1729-8687</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/58225</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Hepatocarcinomul celular: răspândire, factori de risc şi obţiuni de tratament</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>viral chronic hepatitis; liver cirrhosis; liver transplantation; hepatocellular carcinoma; risk factors; treatment methods</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p><em>Liver cancer ranks the 6th place in the structure of oncological morbidity (749000 new cases) and third in cancer mortality structure (692000), representing 7% of all cancer cases. HCC represents more than 90% of primary liver cancer, being the primordial public health problem worldwide. Globally, approximately 54% of HCC cases causally relate to viral hepatitis B (400 million people), 31% of cases are caused by viral hepatitis C (170 million people infected) and the rest – 15% have other causes. The basic treatment of HCC is surgical. When properly selected, candidates resection and liver transplantation offers the best option for development (5-year survival rate is achieved in 60-80% of cases) and there are methods of choice in patients with early-stage tumors.</em></p></cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'><p><em>Рак печени занимает 6-е место в структуре онкологической заболеваемости (749000 новых случаев) и 3-е место в структуре онкологической смертности (692000 случаев) и составляет 7% всех случаев рака. На ГЦК приходится более 90% первичных раковых опухолей печени, что представляет большую проблему здравоохранения во всем мире. В мире около 54% случаев ГЦК связаны с гепатитом В (им страдает 400 млн. человек), 31% случаев обусловлены гепатитом С (им заражено 170 млн. человек), а остальные 15% приходятся на другие причины. Основное лечение ГЦК — хирургическое. У хорошо подобранных кандидатов резекция и трансплантация печени обеспечивают наилучшие исходы (5-летняя выживаемость достигает 60–80%) и служат методом выбора у пациентов с </em><em>ранней стадией опухоли.</em></p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-13440</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13435</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-12084</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-13440</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13440-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> <cfFamilyNames>Таран</cfFamilyNames> <cfFirstNames>Наталья</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13435</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13435-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> <cfFamilyNames>Думбрава</cfFamilyNames> <cfFirstNames>Влада-Татьяна</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-12084</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-12084-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-10-31T24:00:00</cfStartDate> <cfFamilyNames>Тофан-Скутару</cfFamilyNames> <cfFirstNames>Людмила</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>